Add BrightSurf on Google Email

Worry and forgetting keep close company in Alzheimer’s disease

A recent study published in Genomic Psychiatry analyzed the Alzheimer's Disease Neuroimaging Initiative and found that people with frequent anxiety scored lower on a standard test of global cognition. The authors suggest that a single serotonin receptor may be responsible for both worry and cognitive decline in Alzheimer's disease.

SourceGenomic Press·JournalGenomic Psychiatry·DateNov 6, 2026

AFM-Telethon, Nobel Laureate Drew Weissman and neuromuscular disease expert James Dowling join forces to develop the next generation of gene therapies

A new two-year research program aims to develop novel delivery systems for gene therapies, specifically targeting muscle fibres and muscle stem cells using lipid nanoparticles. The project will focus on advancing innovative therapies for neuromuscular disorders, including Duchenne muscular dystrophy and dysferlinopathy.

Gene editing is coming for common diseases. Are we ready?

Gene therapies can already change clinical care, but their use in common conditions raises concerns about permanent harm and competition with existing treatments. Cardiologists propose strategies for determining when genomic therapy is justified, including considering the benefits, risks, and long-term safety monitoring.

SourceMichigan Medicine - University of Michigan·JournalJAMA Internal Medicine·TypeCommentary/editorial·DateOct 20, 2026

UCLA gene therapy pioneer Dr. Donald Kohn elected to National Academy of Medicine

Dr. Donald Kohn, a renowned pediatric bone marrow transplant physician and gene therapy researcher, has been elected to the National Academy of Medicine for his groundbreaking work in blood stem cell gene therapies. His lab has made significant contributions to treating ADA-SCID, severe leukocyte adhesion deficiency-I, and other diseas...

University of Cincinnati study shows proof-of-concept for hydrocephalus gene therapy

Researchers at the University of Cincinnati have developed a proof-of-concept gene therapy that targets and reduces the production of cerebrospinal fluid, potentially providing a minimally invasive treatment for hydrocephalus. The therapy uses an adeno-associated virus to deliver therapeutic genetic material into a patient's cells, wit...

SourceUniversity of Cincinnati·JournalFluids and Barriers of the CNS·TypeExperimental study·DateOct 14, 2026

Turning scar-forming cells into neurons helps restore movement after spinal cord injury

Researchers developed a gene-delivery system that converts reactive astrocytes into functional neurons, improving motor recovery in mice and rats. The system, TRANsCre-DIONE, selectively targets scar-forming cells and reprograms them into neurons, which generate nerve impulses and receive signals from other neurons.

SourceInstitute for Basic Science·JournalExperimental & Molecular Medicine·TypeExperimental study·DateSep 23, 2026

FDA approves first gene therapy treatment for Sanfilippo syndrome type A, developed at the Abigail Wexner Research Institute at Nationwide Children’s Hospital

The FDA approved FAYUVI, a gene therapy treatment for pediatric patients with Sanfilippo Syndrome Type A, following years of research at the Abigail Wexner Research Institute. The treatment, developed by Nationwide Children's Hospital, is the fourth gene therapy to gain FDA approval from the institution.

First-in-human pilot trial for new sickle cell disease gene therapy approach proves quicker, more efficient than industry average

Researchers from Boston Children's Hospital have developed a new gene therapy approach that collects enough stem cells in a single hospital admission, improving turnaround time for genetically altering and infusing cells. The approach has shown long-term stability and safety, with patients not experiencing any adverse effects.

SourceBoston Children's Hospital·JournalBlood·DateAug 25, 2026

Bioinspired nanoparticles deliver gene editing to lower “bad” cholesterol

Researchers developed a bioinspired lipid nanoparticle that delivered gene-editing machinery to the liver, reducing low-density lipoprotein (LDL) cholesterol by over 20% and showing fewer signs of inflammation and toxicity. The nanoparticles also demonstrated positive effects on inflammation and healthy blood flow in cell experiments.

Next-gen mRNA therapeutics get a new delivery vehicle

Researchers at Nagoya University developed a new delivery vehicle for circular RNA (cirRNA) using a novel lipid nanoparticle, FL0445-LNP, which improves the stability and efficacy of mRNA-based therapeutics. The technology has potential applications in cancer vaccines, genome editing, and protein supplements.

SourceNagoya University·JournalCell Biomaterials·TypeExperimental study·DateAug 19, 2026

Scientists at UMass Chan Medical School develop microRNA-based gene therapy that halts ALS progression in mice

Researchers at UMass Chan Medical School have developed a microRNA-based gene therapy that suppresses mutant SOD1 production, delaying disease onset by 60 days and extending lifespan by 100 days in mice models of ALS. The therapy, delivered via adeno-associated virus (AAV) vector, preserves motor neurons and maintains neuromuscular con...

SourceUMass Chan Medical School·JournalNature Communications·TypeExperimental study·DateJul 29, 2026

Gene therapy reverses Fragile X deficits in mice

Researchers developed a gene therapy that restored normal brain activity and improved behavior in mice with Fragile X syndrome by replacing the missing FMRP protein. The treatment administered during early development showed significant improvements in cognitive flexibility, social interactions, and probabilistic reversal learning.

SourceUniversity of California - Riverside·JournalMolecular Therapy — Nucleic Acids·TypeExperimental study·DateJun 18, 2026

Novel gene therapy platform restores muscle function in models of Duchenne muscular dystrophy

Researchers developed a novel gene therapy platform that successfully restored muscle function in preclinical models of Duchenne muscular dystrophy by delivering full-length mRNA of the DMD gene via engineered extracellular vesicles. The treatment showed improved muscle strength, endurance, and function without serious side effects.

SourceUniversity of Texas M. D. Anderson Cancer Center·JournalNature Biomedical Engineering·DateJun 11, 2026

New therapy may reverse autism-related brain deficits

Researchers identified a promising new strategy for reversing autism-related brain deficits by targeting a specific glycine transporter. The therapy restored NMDA receptor function in mouse models and human brain organoids, improving behavioral abnormalities such as social interaction and repetitive behaviors.

SourceInstitute for Basic Science·JournalNature Communications·TypeExperimental study·DateJun 9, 2026

UMass Chan scientists develop gene editing technology capable of rewriting entire chapters of the genome

Researchers have developed a new gene editing technology called 'prime assembly' that allows efficient insertion of large DNA segments into the human genome. This innovation enables treatment of genetic diseases by replacing entire genes, promising substantial progress in treating conditions with multiple mutations.

SourceUMass Chan Medical School·JournalNature·TypeExperimental study·DateMay 13, 2026

Cystic fibrosis: research advances

A study coordinated by the University of Trento has identified a gene therapy for individuals with cystic fibrosis caused by a specific mutation, offering new hope for those currently dependent on drugs. The therapy uses advanced gene editing technology to correct the DNA mutation responsible for the disease.

SourceUniversità di Trento·JournalScience Translational Medicine·TypeExperimental study·DateApr 23, 2026

Hearing restoration from gene therapy for inherited deafness lasts years, new trial results show

A new international study shows that gene therapy targeting the OTOF gene successfully restored hearing in most participants, with significant improvements in speech perception and language skills. The treatment remained safe and effective for up to 2.5 years, offering new hope for individuals with inherited deafness.

SourceMass Eye and Ear·JournalNature·TypeRandomized controlled/clinical trial·DateApr 22, 2026

Gene therapy for Duchenne muscular dystrophy: Genethon confirms two-year efficacy in patients treated with its drug candidate GNT0004 at therapeutic dose in the first phase of its clinical trial

Genethon's GNT0004 gene therapy shows long-term efficacy in patients with Duchenne muscular dystrophy, maintaining clinical efficacy and safety at two years. The trial included 72 boys aged 6-10 with retained walking ability, treated with GNT0004 at a therapeutic dose.